Clinical outcomes and response to treatment of patients receiving topical treatments for pyoderma gangrenosum: a prospective cohort study

Background: pyoderma gangrenosum (PG) is an uncommon dermatosis with a limited evidence base for treatment. Objective: to estimate the effectiveness of topical therapies in the treatment of PG. Methods: prospective cohort study of UK secondary care patients with a clinical diagnosis of PG suit...

Full description

Bibliographic Details
Main Authors: Thomas, Kim S., Ormerod, Anthony D., Craig, Fiona E., Greenlaw, Nicola, Norrie, John, Mitchell, Eleanor, Mason, James M., Johnston, Graham A., Wahie, Shyamal, Williams, Hywel C.
Format: Article
Published: Elsevier 2016
Subjects:
Online Access:https://eprints.nottingham.ac.uk/35997/
_version_ 1848795205406294016
author Thomas, Kim S.
Ormerod, Anthony D.
Craig, Fiona E.
Greenlaw, Nicola
Norrie, John
Mitchell, Eleanor
Mason, James M.
Johnston, Graham A.
Wahie, Shyamal
Williams, Hywel C.
author_facet Thomas, Kim S.
Ormerod, Anthony D.
Craig, Fiona E.
Greenlaw, Nicola
Norrie, John
Mitchell, Eleanor
Mason, James M.
Johnston, Graham A.
Wahie, Shyamal
Williams, Hywel C.
author_sort Thomas, Kim S.
building Nottingham Research Data Repository
collection Online Access
description Background: pyoderma gangrenosum (PG) is an uncommon dermatosis with a limited evidence base for treatment. Objective: to estimate the effectiveness of topical therapies in the treatment of PG. Methods: prospective cohort study of UK secondary care patients with a clinical diagnosis of PG suitable for topical treatment (recruited July 2009 to June 2012). Participants received topical therapy following normal clinical practice (mainly Class I-III topical corticosteroids, tacrolimus 0.03% or 0.1%). Primary outcome: speed of healing at 6 weeks. Secondary outcomes: proportion healed by 6 months; time to healing; global assessment; inflammation; pain; quality-of-life; treatment failure and recurrence. Results: Sixty-six patients (22 to 85 years) were enrolled. Clobetasol propionate 0.05% was the most commonly prescribed therapy. Overall, 28/66 (43.8%) of ulcers healed by 6 months. Median time-to-healing was 145 days (95% CI: 96 days, ∞). Initial ulcer size was a significant predictor of time-to-healing (hazard ratio 0.94 (0.88;80 1.00); p = 0.043). Four patients (15%) had a recurrence. Limitations: No randomised comparator Conclusion: Topical therapy is potentially an effective first-line treatment for PG that avoids possible side effects associated with systemic therapy. It remains unclear whether more severe disease will respond adequately to topical therapy alone.
first_indexed 2025-11-14T19:28:23Z
format Article
id nottingham-35997
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T19:28:23Z
publishDate 2016
publisher Elsevier
recordtype eprints
repository_type Digital Repository
spelling nottingham-359972020-05-04T18:07:44Z https://eprints.nottingham.ac.uk/35997/ Clinical outcomes and response to treatment of patients receiving topical treatments for pyoderma gangrenosum: a prospective cohort study Thomas, Kim S. Ormerod, Anthony D. Craig, Fiona E. Greenlaw, Nicola Norrie, John Mitchell, Eleanor Mason, James M. Johnston, Graham A. Wahie, Shyamal Williams, Hywel C. Background: pyoderma gangrenosum (PG) is an uncommon dermatosis with a limited evidence base for treatment. Objective: to estimate the effectiveness of topical therapies in the treatment of PG. Methods: prospective cohort study of UK secondary care patients with a clinical diagnosis of PG suitable for topical treatment (recruited July 2009 to June 2012). Participants received topical therapy following normal clinical practice (mainly Class I-III topical corticosteroids, tacrolimus 0.03% or 0.1%). Primary outcome: speed of healing at 6 weeks. Secondary outcomes: proportion healed by 6 months; time to healing; global assessment; inflammation; pain; quality-of-life; treatment failure and recurrence. Results: Sixty-six patients (22 to 85 years) were enrolled. Clobetasol propionate 0.05% was the most commonly prescribed therapy. Overall, 28/66 (43.8%) of ulcers healed by 6 months. Median time-to-healing was 145 days (95% CI: 96 days, ∞). Initial ulcer size was a significant predictor of time-to-healing (hazard ratio 0.94 (0.88;80 1.00); p = 0.043). Four patients (15%) had a recurrence. Limitations: No randomised comparator Conclusion: Topical therapy is potentially an effective first-line treatment for PG that avoids possible side effects associated with systemic therapy. It remains unclear whether more severe disease will respond adequately to topical therapy alone. Elsevier 2016-08-05 Article PeerReviewed Thomas, Kim S., Ormerod, Anthony D., Craig, Fiona E., Greenlaw, Nicola, Norrie, John, Mitchell, Eleanor, Mason, James M., Johnston, Graham A., Wahie, Shyamal and Williams, Hywel C. (2016) Clinical outcomes and response to treatment of patients receiving topical treatments for pyoderma gangrenosum: a prospective cohort study. Journal of the American Academy of Dermatology . ISSN 1097-6787 (In Press) Pyoderma gangrenosum Topical therapy Corticosteroid Tacrolimus Side effects Cohort http://www.sciencedirect.com/science/article/pii/S0190962216303942 doi:10.1016/j.jaad.2016.06.016 doi:10.1016/j.jaad.2016.06.016
spellingShingle Pyoderma gangrenosum
Topical therapy
Corticosteroid
Tacrolimus
Side effects
Cohort
Thomas, Kim S.
Ormerod, Anthony D.
Craig, Fiona E.
Greenlaw, Nicola
Norrie, John
Mitchell, Eleanor
Mason, James M.
Johnston, Graham A.
Wahie, Shyamal
Williams, Hywel C.
Clinical outcomes and response to treatment of patients receiving topical treatments for pyoderma gangrenosum: a prospective cohort study
title Clinical outcomes and response to treatment of patients receiving topical treatments for pyoderma gangrenosum: a prospective cohort study
title_full Clinical outcomes and response to treatment of patients receiving topical treatments for pyoderma gangrenosum: a prospective cohort study
title_fullStr Clinical outcomes and response to treatment of patients receiving topical treatments for pyoderma gangrenosum: a prospective cohort study
title_full_unstemmed Clinical outcomes and response to treatment of patients receiving topical treatments for pyoderma gangrenosum: a prospective cohort study
title_short Clinical outcomes and response to treatment of patients receiving topical treatments for pyoderma gangrenosum: a prospective cohort study
title_sort clinical outcomes and response to treatment of patients receiving topical treatments for pyoderma gangrenosum: a prospective cohort study
topic Pyoderma gangrenosum
Topical therapy
Corticosteroid
Tacrolimus
Side effects
Cohort
url https://eprints.nottingham.ac.uk/35997/
https://eprints.nottingham.ac.uk/35997/
https://eprints.nottingham.ac.uk/35997/